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Dendritic cells (DCs) are central in maintaining the intricate balance between immunity and
tolerance by orchestrating adaptive immune responses. Being the most potent antigen
presenting cells, DCs are capable of educating naïve T cells into a wide variety of effector
cells ranging from immunogenic CD4+ T helper cells and cytotoxic CD8+ T cells to
tolerogenic regulatory T cells. This education is based on three fundamental signals.
Signal I, which is mediated by antigen/major histocompatibility complexes binding to
antigen-speciﬁcT cell receptors, guarantees antigen speciﬁcity.The co-stimulatory signal II,
mediated by B7 family molecules, is crucial for the expansion of the antigen-speciﬁcT cells.
The ﬁnal step is T cell polarization by signal III, which is conveyed by DC-derived cytokines
and determines the effector functions of the emerging T cell. Although co-stimulation is
widely recognized to result from the engagement ofT cell-derived CD28 with DC-expressed
B7 molecules (CD80/CD86), other co-stimulatory pathways have been identiﬁed. These
pathways can be divided into two groups based on their impact on primedT cells.Whereas
pathways delivering activatory signals to T cells are termed co-stimulatory pathways,
pathways delivering tolerogenic signals to T cells are termed co-inhibitory pathways. In
this review, we discuss how the nature of DC-derived signal II determines the quality of
ensuingT cell responses and eventually promoting either immunity or tolerance. A thorough
understanding of this process is instrumental in determining the underlying mechanism of
disorders demonstrating distorted immunity/tolerance balance, and would help innovating
new therapeutic approaches for such disorders.
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INTRODUCTION
The immune system is endowed with the unique capacity to pro-
tect against invading pathogens, yet not react to self. Among the
different constituents of the immune system, dendritic cells (DCs)
play a central role in drawing the thin line between immunity
and tolerance. Discovered in 1973 (Steinman and Cohn, 1973),
DCs are recognized as the most potent antigen presenting cells
(APCs). Their ability to initiate and modulate various forms of T
cell responses, earned them the position of being master orches-
trators of adaptive immunity (Banchereau and Steinman, 1998).
DCs are spread throughout the body, residing in different tissues as
sentinels,monitoring their surrounding environment for any signs
of danger. Equipped with pathogen recognition receptors (PRRs),
DCs are capable of sensing pathogenic invasion (Medzhitov and
Janeway Jr., 2002) and self-structures associatedwith cellular stress
(Matzinger, 2002). Upon danger sensing, DCs will undergo func-
tional changes, also known as maturation, crucial for the ensuing
induction of T cell responses (Banchereau et al., 2000). A hallmark
of DC maturation is the expression of the chemokine receptor
CCR7 that allows mature DCs to migrate to draining lymphoid
tissues where they activate naïve T cells in a process based on
three signals. The ﬁrst signal results from the ligation of T cell
receptors (TCRs) to pathogen-derived peptide antigens that are
presented by major histocompatibility complex (MHC) molecules
of DCs, which are upregulated upon maturation. This principal
stimulation signal is important to assure antigen speciﬁcity of the
immune response. Although TCR triggering is crucial for naïve
T cell activation, it is not sufﬁcient by itself to initiate an efﬁca-
cious immune response. The concept of a second co-stimulatory
signal was ﬁrst introduced by Lafferty and Woolnough (1977).
They deduced from organ transplantation studies that alloanti-
gens presented by transplanted tissues failed to elicit any immune
responses unless accompanied by hematopoietic stimulator cells
(Lafferty and Woolnough, 1977). This concept was corroborated
by seminal observations by the group of Schwartz, implying that T
cells activated solely by TCR engagementwere rendered unrespon-
sive and anergic (Jenkins and Schwartz, 1987). This was followed
by the discovery of the main elements of co-stimulation: CD28
(Aruffo and Seed, 1987) and CD80 (Freeman et al., 1989), the
latter being initially identiﬁed as a B cell activation marker and
eventually recognized as the ligand of CD28 (Linsley et al., 1990).
Subsequently, more pathways contributing to signal II were iden-
tiﬁed. Based on the nature of their signal, these molecules can be
divided into co-stimulatorymolecules that promoteT cell prolifer-
ation, and co-inhibitory molecules that attenuate T cell responses.
The nature of signal II is vital in determining the T cell response,
which is further deﬁned by a third polarizing signal. This third sig-
nal promotes the selective development of naïve T cells into one of
the identiﬁed types of effector or tolerogenic T cells (De Jong et al.,
2005). Although signal III is generally recognized to be mediated
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by soluble DC-derived cytokines, there are indications that sig-
nal II may also contribute to T cell polarization. A ﬁnal putative
DC-derived signal is suggested to provide polarized T cells with
homing directions to the site of infection or injury (Sigmunds-
dottir and Butcher, 2008). Thus, DCs control the delicate balance
between immunity and tolerance through the signals they convey
to T cells.
Although the combined effect of all DC-derived signals is
important for full blown T cell responses, signal II is key for
allowing these responses and licensing them to become either
immunogenic or tolerogenic. Here, we shed light on the mul-
tifaceted signal II by reviewing current knowledge of to date
identiﬁed co-stimulatory and co-inhibitory pathways (Figure 1),
their mode of action, relation to disease, and any possible clinical
applications based on utilizing these pathways.
CO-STIMULATORY MOLECULES
CD80/CD86/CD28 PATHWAY
Following the discovery of the CD80/CD28 interaction, B7-2
(CD86) was identiﬁed as a second ligand for CD28 (Azuma et al.,
1993). The CD80/CD86/CD28 pathway was suggested to deliver
the strongest co-stimulatory pathway asCD28-deﬁcient cells failed
to proliferate in the presence of APCs (Green et al., 1994). The con-
sequences of CD28 engagement by its ligands comprise stimula-
tion of T cell proliferation, dramatic upregulation of IL-2 (Linsley
et al., 1991a), promotion of T cell survival by enhancing Bcl-XL
expression (Boise et al., 1995), and enhanced glycolytic ﬂux to
meet energetic requirements associated with a sustained response
(Frauwirth et al., 2002). Those effects were shown to be dependent
on activating the signaling cascades of phosphoinositide-3 kinase
(PI3K), protein kinase B (PKB, also known as Akt), and nuclear
factor kappaB (NF-κB; Song et al., 2008).
Several reports pointed out a possible role for CD28 signal-
ing in T cell polarization. Murine T cells were shown to produce
enhanced levels of IL-4 and IL-5, characteristic for T helper (Th)
2, upon strong CD28 stimulation (Rulifson et al., 1997). Strong
CD28 signaling was also demonstrated to inhibit Th17 responses
(Purvis et al., 2010). Although it is generally accepted that mem-
ory T cells, unlike naives, are less dependent on co-stimulation via
CD28, it was shown that this co-stimulatory pathway is important
in controlling T cell recall responses (Ndejembi et al., 2006).
In addition to its key role in initiating and sustaining efﬁcient
T cell responses, the CD28 pathway is also involved in control-
ling immune tolerance. Co-stimulation of developing thymocytes
by CD28 was shown to induce the expression of Foxp3 and pro-
mote the differentiation of regulatory T cells (Tregs; Tai et al.,
2005). Furthermore, T cell activation in the absence of CD28 co-
stimulation leads to a state of anergy characterized by dramatically
reduced production of IL-2 and other effector cytokines upon sub-
sequent TCR triggering (Schwartz, 1997). There is ample evidence
that DCs utilize this mechanism to maintain tolerance to self. At
steady state conditions, immature DCs present self-derived anti-
gens accompanied by low levels of CD80/CD86 and therefore fail
to supply speciﬁc T cells with adequate signal II, leading eventu-
ally to the deletion, anergy, or regulation of auto-reactive T cells
that escaped thymic selection (Steinman and Nussenzweig, 2002).
Thus, the CD80/CD86/CD28 pathway is as involved in promoting
tolerance as in mediating immunity.
FIGURE 1 | Co-stimulatory and co-inhibitory molecules and their cognate ligands. DC-derived signal II can promoteT cell activation when conveyed by
co-stimulatory molecules, or can attenuate T cell responses when conveyed by co-inhibitory molecules.
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Since many immunogenic tumors lack expression of CD80 and
CD86, it was postulated that tumor-inﬁltrating T cells would
receive chronic TCR stimulation without co-stimulation lead-
ing to T cell anergy. This hypothesis was tested by inducing the
expression of CD80/CD86 molecules on tumor cells prior to injec-
tion into mice. Forced expression of CD80/CD86 in tumor cells
resulted into CD8+ T cell-dependent tumor rejection (Townsend
and Allison, 1993). However, this method had barely any effect
on pre-established tumors (Fallarino et al., 1997), implying that
other pathways promoting immune tolerance toward established
tumors are involved.
CD40/CD40L PATHWAY
CD40 was the ﬁrst co-stimulatory molecules to be identiﬁed from
the tumor necrosis factor (TNF) receptor (TNFR) family. First
discovered as B cell receptor, CD40 is also expressed by DCs,
macrophages, epithelial cells, and even activated T cells. Its lig-
and (CD40L or CD154), a member of the TNF family, is expressed
not only by activated T cells, but also by natural killer (NK) cells
and plasmacytoid DCs (pDCs; Quezada et al., 2004). In addi-
tion to promoting humoral immunity by activating B cells, the
CD40/CD40L pair is pivotal for cellular immunity as it medi-
ates a dialog between T cells and DCs. Indeed, CD40 engagement
on DCs was shown to activate NF-κB pathway (Quezada et al.,
2004) and consequently inducing DC maturation (Caux et al.,
1994) and enhancing DC longevity (Miga et al., 2001). Initially,
CD40-induced maturation of DCs was suggested to be sufﬁcient
in licensing CD8+ cytotoxic responses (Schoenberger et al., 1998).
However, further investigation in the CD40 pathway revealed that
additional signals are necessary for optimal DC activation. CD40
cross-linking alone is not enough to induce IL-12 production,
necessary for cytotoxic and Th1 responses, but DC pre-activation
by microbial products followed by CD40 ligation dramatically
increased IL-12 production (Schulz et al., 2000). This ﬁnding indi-
cates that combined triggering of CD40 and PRRs, like Toll-like
receptors (TLRs), is critical for DC licensing. The CD40-induced
IL-12 also implies a central role for CD40/CD40L pathway in
T cell differentiation, by favoring Th1 polarization. Blocking
CD40/CD40L interactions lead to abrogated Th1 responses with
reciprocal upregulation of Th2 cytokines (Hancock et al., 1998).
The adjuvant effect of CD40 ligation, reﬂected by DC activa-
tion, prompted the application of agonistic anti-CD40 antibodies
for cancer therapy. Injecting agonistic anti-CD40 antibodies
evoked cytotoxic T cell responses and eradicated the tumor in a
mouse model of lymphoma (French et al., 1999). Furthermore,
application of fully humanized anti-CD40 agonistic antibody
resulted in objective partial responses in 14% of advanced solid
tumor patients (Vonderheide et al., 2007). A similar approach was
based on the administration of soluble CD40L, which was less
efﬁcient as it lead to partial responses in 6% of treated tumor
patients (Vonderheide et al., 2001). More clinical trials applying
CD40 ligation, singularly or in conjunction with other therapeutic
modalities, were carried out and showed promising results (Khong
et al., 2012).
Due to its activatory nature, the CD40/CD40L is decisive in
regulating tolerance. It was shown that DCs derived from CD40-
deﬁcientmice conferred tolerancebypriming IL-10 secretingTregs
(Martin et al., 2003). This effect on tolerance prompted inves-
tigating the possibility of exploiting CD40 blocking to enhance
allograft survival. Although applying anti-CD40L antibodies as
a monotherapy was able to block many effector mechanisms, it
failed to induce sufﬁcient allograft tolerance (Jones et al., 2000).
However, combinations with other immunosuppressive therapies
such as cytotoxic T lymphocyte (CTL)-associated antigen-4-
immunoglobulin (CTLA-4-Ig; Larsen et al., 1996) and rapamycin
(Li et al., 1998) were shown to result in long-term graft survival.
Collectively, CD40/CD40L pathway, in conjunction with other
pathways, is vital for initiating active immunity and regulating
tolerance.
ICOSL/ICOS PATHWAY
The inducible T cell co-stimulator (ICOS) was identiﬁed as the
third member of the CD28/CTLA-4 family of co-stimulatory
molecules (Hutloff et al., 1999). ICOS expression by T cells
requires prior TCR activation andCD28 co-stimulation (McAdam
et al., 2000). The ligand (ICOSL) is expressed by DCs (Wang
et al., 2000), B cells, and a variety of non-hematopoietic tissues
(Ling et al., 2000). ICOSL/ICOS pathway exerts its co-stimulatory
effects on already activated T cells by supporting proliferation
and cytokine production (Hutloff et al., 1999). Additionally, ICOS
is proposed to play an important role in T cell polarization.
Initially, ICOSL/ICOS was suggested to support Th2 responses.
Blocking ICOSL/ICOS interactions was shown to block Th2-lead
airway responses without inﬂuencing Th1-mediated inﬂamma-
tion (Coyle et al., 2000). Similarly, another study showed that
the majority of T cells expressing ICOS in vivo co-produced
Th2-type cytokines (Lohning et al., 2003). In contrast, disrupt-
ing ICOSL/ICOS pathway was found to inhibit Th1-mediated
disorders like allograft rejection (Guo et al., 2002) and experimen-
tal allergic encephalomyelitis (Rottman et al., 2001). ICOS was
shown to be involved driving Th17 responses (Park et al., 2005),
further complicating the role of ICOSL/ICOS in T cell polar-
ization. An attempt to resolve this controversy was by showing
that engaging ICOS on activated T cells ampliﬁed the effec-
tor responses of these cells regardless of their polarized state
(Wassink et al., 2004).
Beneﬁting of the activatory effect of ICOSL/ICOS pathway
in the context of cancer therapy was evaluated. Induced ICOSL
expression on tumor cells was demonstrated to promote tumor
regression by inducing CD8 cytotoxicity (Liu et al., 2001). Never-
theless, this strategywas ineffective in case of weakly immunogenic
tumors (Ara et al., 2003). Surprisingly, it was recently revealed that
tumor cell-expressed ICOSL augments Treg activation and expan-
sion within the tumor local environment (Martin-Orozco et al.,
2010). This suggests that triggering ICOSL/ICOS pathwaymay not
be the most optimal option for cancer treatment. On the contrary,
blocking its ICOSL/ICOS-mediated suppression may be beneﬁcial
in cancer therapy.
The tolerogenic effect of ICOSL/ICOS pathway is not restricted
to tumors, as there are indications of its involvement in maintain-
ing immune tolerance. ICOS-deﬁcient mice displayed reduced
numbers of natural Tregs (nTregs), which may be owed to a
decrease in survival and/or proliferation of these cells (Burmeister
et al., 2008). Another indication of ICOS involvement in tolerance
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is the ﬁnding that ICOS triggering onTcells dramatically increased
the production of the anti-inﬂammatory cytokine IL-10 (Hutloff
et al., 1999). Consistently, high ICOS expression by T cells was
selectively associated with the anti-inﬂammatory IL-10 (Lohning
et al., 2003). These ﬁndings argue for targeting ICOSL/ICOS path-
way to induce tolerance for therapeutic purposes. However, it is
very important to clearly dissect the conditions under which this
pathway induces activation or tolerance.
CD70/CD27 PATHWAY
CD70 is another member of the TNF family of co-stimulatory
molecules. Its ligand CD27 was identiﬁed ﬁrst as a novel T cell
differentiation antigen (van Lier et al., 1987). The contribution of
CD27 to immunity was later recognized to be dependent on its
binding partner CD70, which is expressed under the control of
antigen receptors and TLRs in lymphocytes and DCs, respectively
(Tesselaar et al., 2003). Similar to CD40, engaging CD27 induced
the activation of NF-κB pathway (Akiba et al., 1998). The ﬁrst
indication of the co-stimulatory properties of the CD70/CD27
pathway was provided by triggering CD27, which augmented
CD3-induced T cell proliferation (van Lier et al., 1987). This effect
was later explained by promoting survival of newly stimulated
T cells, in contrast to CD28 that prompts cell cycle entry and
induces proliferation (Hendriks et al., 2003). This survival effect
relies completely on IL-2 receptor signaling and the autocrine
production of IL-2 (Peperzak et al., 2010).
The contribution of CD70/CD27 pathway to T cell polarization
is debatable. CD8+ T cells from CD27 knockout mice maintained
the capacity of differentiation into CTLs and interferon-gamma
(IFN-γ) production, implying that CD27 is not involved in the
development of cytotoxic CD8 responses (Hendriks et al., 2000).
On the other hand, transgenic expression of CD70 on steady state
immature DCs was found to break CD8+ tolerance and permit
the differentiation of effector CD4+ and CD8+ cells from naïve
precursors (Keller et al., 2008). Moreover, the murine CD8α+ DC
subset was revealed to favor the differentiation of Th1 cells in
a CD70-dependent and IL-12-independent mechanism (Soares
et al., 2007). This is further supported by showing that human
Langerhans cells (LCs), an epidermal subset of DCs, are capable of
inducingCD8+ anti-viral responses in aCD70-dependentmanner
(van der Aar et al., 2011). A recent study also demonstrated that
CD70/CD27 pathway impedes the differentiation of Th17 effec-
tor cells and attenuates accompanying autoimmunity in a mouse
model of multiple sclerosis (Coquet et al., 2012). These ﬁndings
imply that CD70 involvement in T cell polarization may depend
on the type of DCs expressing CD70 and the type of stimuli to
which these DCs are exposed.
The activatory effect of CD70/CD27 pathway can be exploited
for anti-tumor therapy. Induced expression of both CD70 and
CD40L by tumor cells was shown to impede tumor growth and
initiate anti-tumor immunity (Couderc et al., 1998). Furthermore,
the application of CD70, encoded in a vaccinia virus, was shown
to confer protection against introduced tumors (Lorenz et al.,
1999). Evidence for possible clinical beneﬁt from mobilizing the
CD70/CD27 pathway was provided by a recent clinical trial utiliz-
ing DCs expressing CD70, CD40L, and constitutively active TLR4
(TriMix-DC) in the treatment of metastatic melanoma patients.
These TriMix-DCs were able to initiate a broad anti-tumor T cell
response, resulting in prolonged progression-free survival (Van
Nuffel et al., 2012). This paves theway for a novel strategy in cancer
immunotherapy based on mobilizing the CD70/CD27 pathway.
Several reports have implicated CD70/CD27 pathway in
autoimmunity. Elevated expression of CD70 by pathogenic T cells
was observed in rheumatoid arthritis (Lee et al., 2007) and lupus
erythematosus patients (Han et al., 2005). Moreover, blocking
CD70/CD27 pathway seems to help ameliorating inﬂammation
in mouse models of arthritis (Oﬂazoglu et al., 2009) and coli-
tis (Manocha et al., 2009). However, the study reporting Th17
inhibiting effects of CD70 signaling (Coquet et al., 2012) may
argue against the blockade of CD70/CD27 pathway, especially
sinceTh17 effector cells are involved in various auto-inﬂammatory
diseases.
OX-40L/OX-40 PATHWAY
OX-40L and OX-40 belong to the TNF family and TNFR fam-
ily, respectively. OX-40, also known as CD134, was ﬁrst described
on activated CD4+ T cells (Paterson et al., 1987). The expres-
sion of OX-40 is in fact restricted to recently antigen-activated
T cells and not naïve or memory T cells, implying that it is
specialized in delivering co-stimulation to activated T cells (Sug-
amura et al., 2004). The ligand, OX-40L (CD252), is expressed
on DCs and macrophages, especially after TLR or CD40 ligation
(Ohshima et al., 1997). Additionally, responding T cells express
OX-40L themselves (Soroosh et al., 2006). Engagement of OX-40
on T cells promotes long-term survival by inducing the expression
of the anti-apoptotic molecules Bcl-2 and Bcl-xL (Rogers et al.,
2001). This study suggests that the differential expression kinetics
of OX-40 and CD28, the latter being constitutively expressed by
T cells, bares functional specialization. Whereas CD28 is essential
for the initial priming of naïve T cells into effector T cells, OX-40 is
crucial for the expansion (later proliferation) and survival of these
effector cells.
Several studies have pointed out a central role for OX-40 in
regulating the balance between Th1 and Th2 responses. Co-
stimulating T cells through OX-40 was shown to induce IL-4
expression and inhibited IFN-γ production (Flynn et al., 1998).
Furthermore, DC treatment with thymic stromal lymphopoietin
(TSLP), known for its Th2 skewing properties, leads to the expres-
sion of OX-40L and the subsequent priming of Th2 cells (Ito et al.,
2005). OX-40-favored Th2 response was proposed to be mediated
by an initial induction of nuclear factor of activated T cells (NFAT)
c1 in an IL-4 receptor-independent manner, followed by an IL-4
receptor-dependent effect on GATA-3 (So et al., 2006). However,
it was shown later that DC-derived OX-40L maintained both Th2
andTh1 responses, owed toOX-40-enhanced survival of effector T
cells regardless of their polarization (Jenkins et al., 2007). Thus, it
seems that the role of OX-40/OX-40L in the differentiation of Th2
cells is restricted to promoting the survival of already established
Th2 cells that differentiated under the effect of other DC-derived
factors.
OX-40/OX-40L is also involved in controlling immune toler-
ance. The ﬁrst evidence of this role is the expression of signiﬁcant
amounts of OX-40 on naturally occurring Foxp3+ Tregs. OX40
signaling appears to be dispensable for the development of nTregs,
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since this population exists in OX-40-deﬁcient mice. However,
OX-40 signaling is important for the survival of nTregs as OX-
40-deﬁcient mice displayed lower counts of this population of
Tregs (Takeda et al., 2004). The effect of OX-40 triggering on
the functions of nTregs remains controversial. Whereas one study
showed that OX-40 signaling in CD4+ T cells render them resis-
tant to suppression by nTregs (Takeda et al., 2004), another study
reported abrogated suppression following OX-40 triggering on
nTregs (Valzasina et al., 2005). Another mechanism by which OX-
40L/OX-40 is assumed to contribute to tolerance regulation is by
inﬂuencing thedevelopmentof inducedTregs (iTregs). Under con-
ditions promoting iTreg differentiation, OX-40 engagement on T
cells was shown to inhibit Foxp3 expression by these T cells (So and
Croft, 2007). Nevertheless, the surrounding environment during
iTreg differentiation seems to determine the outcome of OX-40
signaling, which was reported to promote the expansion of iTregs
if IL-4 and IFN-γ were absent from the milieu (Ruby et al., 2009).
In conclusion, OX-40L/OX-40 appears to be central in maintain-
ing the survival of T cells in general, but its inﬂuence on T cell
functions requires further elucidation.
4-1BBL/4-1BB PATHWAY
4-1BB (CD137) is yet another member of the TNFR family. Its
expression is induced on T cells following TCR activation (Pollok
et al., 1993). The ligand, 4-1BBL of the TNF family, is expressed
on activated APCs (Vinay and Kwon, 1998). Engagement of T cell
4-1BB was reported to induce IL-2 production independently of
CD28, when accompanied by strong TCR signaling (Saoulli et al.,
1998). Furthermore, 4-1BB interactionwith its ligandwas demon-
strated to provide a co-stimulatory signal particularly to CD8+ T
cells, enhancing proliferation, cytotoxicity (Shuford et al., 1997),
and survival (Lee et al., 2002). Similar to other TNFR family mem-
bers, 4-1BB enhanced survival is dependent on NF-κB activation,
which in turn induces the two pro-survival molecules: Bcl-xL and
Bﬂ-1 (Lee et al., 2002). When compared to co-stimulation with
CD80/CD86, 4-1BBL appears to bemore effective in drivingCD8+
memory T cells into a fully differentiated effector state (Bukczyn-
ski et al., 2004). Furthermore, 4-1BB ligation was also shown to
augment Th1 cytokines and suppress Th2 cytokines, implying a
possible role for 4-1BB in T cell polarization (Kim et al., 1998).
Collectively, these properties raised the interest in 4-1BBL/4-1BB
pathway as potential therapeutic target especially in cancer ther-
apy. Several studies demonstrated a beneﬁcial effect of activating
4-1BB in inducing anti-tumor immunity and tumor regression
thereafter (Driessens et al., 2009). Nevertheless, great caution
should be taken before transferring these observations into clinical
applications especially after reporting possible tolerogenic effects
following 4-1BB triggering. Engaging 4-1BB by agonist antibod-
ies was reported to ameliorate the severity of autoimmunity in
murine models of experimental autoimmune encephalomyeli-
tis (EAE) (Sun et al., 2002) and systemic lupus erythematosus
(Foell et al., 2003), and to inhibit rejections of intestinal allo-
grafts in mice (Wang et al., 2003). These ﬁndings imply a link
between 4-1BBL/4-1BB pathway and tolerance. Indeed, 4-1BB
co-stimulation was shown to synergize with IL-2 in promoting
nTreg expansion (Elpek et al., 2007). In an experimental model
of rheumatoid arthritis, treatment with 4-1BB agonist antibodies
inhibited disease progression, which was attributed to the induc-
tion of indoleamine 2,3-dioxygenase (IDO; Seo et al., 2004).
Altogether, 4-1BBL/4-1BB pathway contributes to immunity and
tolerance, allowing multiple therapeutic applications through this
pathway.
GITRL/GITR PATHWAY
Glucocorticoid-induced TNFR related gene (GITR) was ﬁrst dis-
covered as a dexamethasone-induced molecule in murine T cell
hybridomas (Nocentini et al., 1997). The expression of the human
ortholog was subsequently identiﬁed in human lymphocytes and
shown to be independent of glucocorticoid treatment. Similar
to the TNFR family members OX-40 and 4-1BB, GITR is only
expressed on recently activated T cells, implying a role in promot-
ing effector functions rather than involvement in initial priming
of naïve T cells (Gurney et al., 1999). The GITR ligand (GITRL) is
expressed by APCs and is upregulated upon activation (Tone et al.,
2003). GITRL/GITR pathway provides co-stimulation to naïve T
lymphocytes demonstrated by enhanced proliferation and effector
functions in the setting of suboptimal TCR stimulation (Ronchetti
et al., 2004). Additionally, GITR triggering promoted naïve T cell
survival through the activation of NF-κB and mitogen-activated
protein kinase (MAPK) pathways, though it was not sufﬁcient to
inhibit activation-induced cell death initiated by TCR signaling
(Esparza and Arch, 2005). GITRL/GITR pathway does not seem
to have an impact on T cell polarization. Although applying an
agonist antibody against GITR initially enhanced Th2 responses
in a mouse model of helminth infection, this effect was short lived
and GITR-independent (van der Werf et al., 2011).
A role for GITRL/GITR pathway in immune tolerance was ini-
tially demonstrated by the constitutive expression of GITR on
Tregs (Shimizu et al., 2002). Factually, Tregs isolated based on
the expression of GITR could prevent the development of col-
itis induced in an adoptive transfer model (Uraushihara et al.,
2003). However, engaging Treg-expressed GITR, by agonist anti-
bodies, was shown to abrogate their suppressive capacity (Shimizu
et al., 2002). In the beginning, this effect was interpreted by mere
activation of Tregs upon GITR stimulation, but this explanation
was underscored by the fact that Treg preincubation with anti-
GITR did not cause the subsequent loss of suppression (Shimizu
et al., 2002). Eventually, it was revealed that triggering GITR on
effector T cells rendered them resistant to suppression by Treg
(Stephens et al., 2004), providing a plausible explanation for the
anti-tolerogenic effects of GITR stimulation. This postulates a
model whereAPC-expressed GITRL would bind GITR on recently
stimulated T cells allowing them to resist suppression. Simul-
taneously, GITR ligation on Tregs would allow their expansion
and their subsequent domination at later stages of the immune
response (Stephens et al., 2004).
Based on the activatory nature of GITRL/GITR pathway and its
characteristic inhibition of tolerance, employing this pathway in
cancer therapy was evaluated. The administration of an agonistic
antibody against GITR has been shown to augment CD8 anti-
tumor immunity (Cohen et al., 2006). In addition to mobilizing
anti-tumor responses, triggering GITR was also shown to attenu-
ate Treg-mediated suppression within the tumor (Ko et al., 2005),
making GITRL/GITR a promising target for cancer therapy.
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LIGHT/HVEM PATHWAY
The TNFR family member herpes virus entry mediator (HVEM)
was initially discovered as a receptor for herpes simplex virus
(Montgomery et al., 1996). It is expressed on resting T cells,
monocytes, and immature DCs. HVEM has multiple binding
partners: LIGHT and lymphotoxin-α (LT-α) from the TNF super-
family; and CD160 and B and T lymphocyte attenuator (BTLA)
from the Ig superfamily. HVEM interaction with these ligands
creates a complex network of pathways, which collectively reg-
ulates adaptive immune responses (Ware and Sedy, 2011). In
this section we will only focus on the co-stimulatory pathway
resulting from LIGHT/HVEM interactions. LIGHT is expressed
by immature DCs (Tamada et al., 2000a) and is induced upon
activation on T cells, in contrast to HVEM (Morel et al., 2000).
LIGHT/HVEM interaction was revealed to be required for DC-
mediated allogenic T cell responses. Indeed, activating T cell
HVEM enhanced T cell proliferation at suboptimal TCR stimula-
tion conditions (Tamada et al., 2000a). Disrupted LIGHT/HVEM
interaction was shown to result in inhibited T cell prolifer-
ation, further supporting the importance of this pathway in
co-stimulation (La et al., 2002). Similar to other TNFR family
members, HVEM mediates its effects by activating NF-κB path-
way (Harrop et al., 1998). Interestingly, LIGHT/HVEM pathway
can also contribute to T cell activation indirectly by inducing
DC maturation, reminiscent of the role of CD40 in inducing
DC maturation (Morel et al., 2001). LIGHT/HVEM pathway is
also suggested to contribute to T cell polarization. T cells co-
stimulated throughHVEMdisplayed enhanced production of Th1
cytokines (Tamada et al., 2000b). Accordingly, LIGHT-deﬁcient
mice showed reduced IFN-γ levels, prolonging allograft sur-
vival in these mice (Ye et al., 2002). Due to the complexity of
the signaling network of HVEM and LIGHT, reported ﬁndings
should be interpreted as these observations may involve other
pathways.
TIM FAMILY
In addition to the CD28/B7 and TNFR/TNF co-stimulatory fam-
ilies, the recently identiﬁed TIM (T cell Ig domain and mucin
domain) family is a new contributor to signal II. This family
of genes was initially identiﬁed while searching for Th1-speciﬁc
markers (Monney et al., 2002). In humans, threeTIM familymem-
bers: TIM1, TIM3, and TIM4 have been identiﬁed thus far. Mice
posses an additional member: TIM2 (Kuchroo et al., 2008). In
this section we will only focus on TIM3 and TIM4, which were
reported to be expressed by DCs.
TIM3 was ﬁrst discovered as a speciﬁc marker for Th1 cells
(Monney et al., 2002), and was shown to induce the death of these
cells by binding to its ligand galectin-9 (Zhu et al., 2005). TIM3
expression was also detected on DCs, and its ligation by galectin-
9 induced the production of the inﬂammatory cytokine TNF-α.
The absence of TIM3 signaling was shown to result in impaired
TLR responsiveness, implying a synergistic relation between TIM3
and TLR signaling pathways (Anderson et al., 2007). Although
TIM3 triggering on T cells and DCs leads to ERK (extracellular
signal-regulated kinases) phosphorylation and IκBα degradation,
different tyrosine phosphorylation patterns in T cells and DCs
were detected, providing aplausible explanation for the differential
effects of TIM3 between different cell types (Anderson et al.,
2007). Thus far, interactions between DC-expressed TIM3 and
T cell-expressed galectin-9 have not been investigated. However,
previous ﬁndings prompt amodelwhereDC-expressedTIM3pro-
motes inﬂammation and the differentiation of TIM3-expressing
Th1 cells. IFN-γ-induced galectin-9 would interact with TIM3
from other T cells, inducing cell death and thereby self-limiting
the immune response. Additionally, TIM3 is suggested to con-
tribute to tolerance. A crucial role for TIM3 in clearing apoptotic
cells by phagocytosis was recently revealed. Blocking this func-
tion resulted in inhibited cross-presentation of self-antigens and
the development of auto-antibodies (Nakayama et al., 2009). In
a completely different mechanism, TIM3 expressed by tumor-
inﬁltrating DCs was shown to interact with the alarmin HMGB1,
disturbing the recruitment of tumor cell-derived nucleic acids into
DC endosomes, attenuating immune responses to these tumors
(Chiba et al., 2012).
In contrast to the other members of the TIM family, TIM4 is
exclusively expressed by APCs and not by T cells (Meyers et al.,
2005). Through binding to TIM1 on T cells, TIM4 was shown
to provide T cells with a co-stimulatory signal promoting T cell
expansion, cytokine production, and survival. These effects were
mediated by induced phosphorylation of the signaling molecules
LAT (linker of activated T cells), Akt, and ERK1/2 in stimulated
T cells (Rodriguez-Manzanet et al., 2008). Notably, the strength
of TIM4 signal is decisive in determining the stimulatory effect,
as weak TIM4 signaling inhibits T cell proliferation instead of
potentiating it (Meyers et al., 2005). Similarly, TIM4 was shown
to inhibit the proliferation of naïve T cells, which lack the expres-
sion of TIM1 (Mizui et al., 2008). These data imply that TIM4
has at least two binding partners: an activating ligand (TIM1)
and an inhibitory one to be identiﬁed. Through these ligands,
TIM4 exerts bimodal regulation of immune responses. Analogous
to TIM3, the role of TIM4 in regulating immunity is also evi-
dent through mediating the engulfment of apoptotic cells. In vivo
blocking of TIM4 resulted in the development of auto-antibodies
(Miyanishi et al., 2007).
ADHESION MOLECULES PROVIDING CO-STIMULATORY SIGNALS
Leukocyte adhesion and detachment fromother cells is tightly reg-
ulated by adhesion molecules. A speciﬁc set of these molecules is
involved in regulating DC/T cell interactions. This set includes the
following molecules: intercellular adhesion molecule 1 (ICAM-1)
and lymphocyte function-associated antigen-3 (LFA-3), expressed
by DCs, and their respective ligands LFA-1 and CD2, expressed
by T cells. The seminal discovery of the involvement of LFA-
1 in mediating T cell functions prompted a hypothesis that
LFA-1 would act by enhancing adhesion and thereby increas-
ing the range of avidities that can promote antigen recognition
(Springer et al., 1982). Subsequently, ICAM-1 was identiﬁed as
the ligand of LFA-1 (Rothlein et al., 1986). LFA-1 ligation by
ICAM-1 was shown to induce proliferation of TCR-stimulated
T cells in an IL-2-dependent mechanism, proposing that ICAM-
1/LFA-1 interaction as a co-stimulatory pathway (Van Seventer
et al., 1990). In addition to co-stimulation, ICAM-1/LFA-1 inter-
action stabilizes the immunological junction (Bleijs et al., 2001)
and the ICAM-1/LFA-1 pathway appears to contribute to T
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cell differentiation as repeated T cell stimulation with ICAM-1
promoted IFN-γ production by these cells (Semnani et al., 1994).
Moreover, blocking ICAM-1/LFA-1 interactions during T cell
stimulation drastically increased Th2 cytokines (Salomon and
Bluestone, 1998). More recently, ICAM-1/LFA-1 interaction dur-
ing CD8+ T cell priming was demonstrated to be essential for the
establishment of effective T cell memory (Scholer et al., 2008). The
effects of the ICAM-1/LFA-1 pathway are believed to result from
inﬂuencing multiple cellular signaling cascades. LFA-1 was found
to interact with the transcriptional co-activator JAB1, implying an
inﬂuence on c-Jun-driven transcription (Bianchi et al., 2000).
In parallel, T cell CD2 interaction with its ligand LFA-3 was
recognized for contributing to T cell activation by strengthening
the adhesion between T cells andAPCs and thereby enforcing TCR
contact with its ligands (Davis and van der Merwe, 1996). More-
over, CD2 signaling was also shown to restore responsiveness in
anergized human T cells (Boussiotis et al., 1994). CD2 blocking
in vivo was revealed to induce T cell unresponsiveness, further
supporting the notion that LFA-3/CD2 pathway contributes to
immune activation (Xu et al., 2004). Conversely, speciﬁc mobi-
lization of LFA-3/CD2 interactions was demonstrated to induce,
single handedly, non-proliferating Tregs secreting high amounts
of IL-10 (Wakkach et al., 2001). In light of these contradictions,
further characterization of the role of LFA-3/CD2 co-stimulatory
pathway is required.
CO-INHIBITORY MOLECULES
CD80/CD86/CTLA-4 PATHWAY
Cytotoxic T lymphocyte-associated antigen-4 (CD152) is a CD28
homolog that was discovered in 1987 (Brunet et al., 1987). The
closely related structures of these two molecules suggest overlap-
ping functional qualities. Indeed, CTLA-4 binds to CD80 and
CD86, though at greater afﬁnities. However, CTLA-4 was the
ﬁrst described co-stimulatory molecule with inhibitory effects in a
stark contrast to the activatory properties of CD28 (Linsley et al.,
1991b). The effects of CTLA-4 include inhibition of proliferation,
cell cycle progression, and IL-2 synthesis (Walunas et al., 1996).
Additionally, CTLA-4 seems to have an inﬂuence on T cell polar-
ization. T cells lacking CTLA-4 expression were shown to adopt a
Th2 phenotype (Bour-Jordan et al., 2003). Furthermore, neutral-
izing CTLA-4 signaling in T cells was recently shown to enhance
IL-17 production and promote the differentiation of Th17 cells
(Ying et al., 2010).
The prominent role of CTLA-4 in tolerance is clearly demon-
strated by CTLA-4-deﬁcient mice, which succumb at 3–4 weeks of
age tomassive lymphoproliferative disease (Tivol et al., 1995). Fur-
thermore, the suppressive functions of naturally occurring Tregs,
which constitutively express CTLA-4, were dependent on CTLA-4
signaling (Read et al., 2000), corroborating its role in tolerance.
CTLA-4 contribution to tolerance is postulated to arise from con-
trolling T cell responses in an intrinsic or extrinsic manner (Rudd
et al., 2009). First, CTLA-4 antagonizes the CD28 stimulatory
signaling by competing with CD28 on binding to CD80/CD86.
Interestingly, CTLA-4 expression on cells is induced in a CD28-
dependent mechanism (Alegre et al., 1996), implying that CTLA-4
serves as an internal checkpoint that prohibits excessive stimula-
tion by CD28. Extrinsic inhibitory effects of CTLA-4 are suggested
to be exerted through different mechanisms. CTLA-4 molecules
expressed by Tregs were shown to engage CD80/CD86, expressed
by DCs, promoting the activity of IDO. The modiﬁed catabolic
properties of DCs lead to localized deprivation of tryptophan and
thereby reduced T stimulatory capacity of these DCs (Fallarino
et al., 2003). Another suggestedmechanism for the extrinsic effects
of CTLA-4was demonstrated by the capacity of CTLA-4 to capture
CD86, expressed byAPCs, internalize it for ensuing degradation in
a process called trans-endocytosis (Qureshi et al., 2011). Tregswere
also observed to suppress T cells by establishing a direct interaction
through CTLA-4, which binds to CD80 and CD86 expressed by
those T cells (Taylor et al., 2004). Finally, unstimulated T cells were
revealed to produce a soluble form of CTLA-4, which may possibly
convey the inhibitory effects to other cells (Magistrelli et al., 1999).
Collectively, CTLA-4 is unequivocally vital for tolerance.
Due to its role in maintaining tolerance, blocking CTLA-4
interaction with CD80 and CD86 was postulated to promote
anti-tumor immunity. Indeed, in vivo administration of block-
ing antibodies against CTLA-4 resulted into effective anti-tumor
immunity and tumor rejection (Leach et al., 1996). Neverthe-
less, CTLA-4 blockade efﬁcacy in tumor therapy was correlated
with the stage and immunogenicity of the tumor. At early stages
small tumors were sensitive to the effects of CTLA-4 blockade
(Shrikant et al., 1999), whereas advanced tumors were resistant
due to the strongly tumor-induced T cell tolerance (Sotomayor
et al., 1999). In an attempt to circumvent this hurdle, anti-CTLA-
4 blocking antibodies were tested in combination with other
therapeutic modalities. Combined anti-CTLA-4 application and
Treg depletion resulted in maximal tumor rejection, which was
dependent on the expansion of tumor-speciﬁc CD8+ T cells
(Sutmuller et al., 2001). Those promising experimental observa-
tions lead to the development of two fully human anti-CTLA-4
antibodies: ipilimumab (Bristol-Myers Squibb, New York, NY,
USA) and tremelimumab (Pﬁzer, New York, NY, USA). Early
clinical trials in metastatic melanoma and ovarian carcinoma
patients demonstrated that blocking CTLA-4 resulted in exten-
sive tumor necrosis with lymphocyte and granulocyte inﬁltrates
in a large number of patients (Hodi et al., 2003). Further large
scale clinical trials have shown irrefutable evidence of the efﬁcacy
of anti-CTLA-4 antibodies, leading eventually to FDA approval
of these antibodies (Kirkwood et al., 2012). Despite its novelty,
this therapeutic strategy is challenged by autoimmune complica-
tions resulting from the administration of anti-CTLA-4 antibodies
(Sanderson et al., 2005).
The tolerogenic effects arising from CTLA-4 engagement
with CD80/CD86 can also be utilized for inducing tolerance
toward transplanted tissues. This notion has been supported by
observations in animal experimental models. Administration of
recombinantCTLA-4-Ig fusionprotein after renal or cardiac trans-
plantation enhanced allograft acceptance and reduced inﬂamma-
tory responses (Azuma et al., 1996). This led to the development
of humanized CTLA-4-Ig (Belatacept). Kidney transplantation
patients receiving Belatacept showed reduced allograft rejection
and maintained better renal functions, compared to patients
receiving cyclosporine. These ﬁndings resulted in gaining FDA
approval for using Belatacept for the prevention of acute rejection
post-renal transplant (Vincenti et al., 2011).
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PD-L1/PD-L2/PD-1 PATHWAY
Programed cell death-1 (PD-1) is another member of the CD28
family that is expressed by activated T and B cells (Agata et al.,
1996). Two ligands were identiﬁed to interact with PD-1: PD-
L1 (Dong et al., 1999) and PD-L2 (Latchman et al., 2001). Those
ligands are characterized by differential expression patterns. PD-
L1 is constitutively expressed and further enhanced on activated
lymphocytes, including Tregs and DCs. It is also expressed by
a wide variety of non-hematopoietic cell types including the
vascular endothelial cells, neurons and pancreatic islet cells. In
contrast, PD-L2 expression is restricted to DCs and macrophages
under certain conditions (Greenwald et al., 2005). Interestingly,
PD-L2 displays three times higher binding afﬁnity to PD-1 in
comparison to PD-L1, which on the other hand was also iden-
tiﬁed to bind to CD80 (Butte et al., 2007). The varying binding
and expression properties of PD-L1 and PD-L2 suggest distinct
functions in regulating T cell responses. Along with its ligands
PD-1, is recognized for its vital role in regulating adaptive immune
responses (Sharpe et al., 2007). Indeed, triggering of PD-1 by one
of its ligands during TCR signaling can block T cell proliferation,
cytokine production and cytolytic activity, and impair T cell sur-
vival (Riley, 2009). The intracellular domain of PD-1 contains an
immunoreceptor tyrosine-based inhibitory motif (ITIM) as well
as an immunoreceptor tyrosine-based switchmotif (ITSM),which
are phosphorylated upon ligand engagement. Subsequently pro-
tein phosphatases, such as Src homology phosphatase-1 (SHP-1)
and SHP-2, are recruited to TSM where they are activated and
inhibit proximal TCR signaling events by dephosphorylating key
intermediates in theTCR signaling cascade (Chemnitz et al., 2004).
Similar to CTLA-4, triggering PD-1 limits glucose metabolism
and Akt activation, albeit through different mechanisms (Chem-
nitz et al., 2004). Consistently, a recent study also demonstrated
that PD-1 exerted its inhibitory effects by affecting Akt and Ras
pathways and thereby inhibiting cell cycle progression and T cell
proliferation (Patsoukis et al., 2012).
The ﬁrst indication of the importance of PD-1 in immune
tolerance came from PD-1-deﬁcient mice, which developed
strain-speciﬁc autoimmunity. The absence of PD-1 caused the
development of cardiomyopathy secondary to the production
of auto-antibodies against cardiac troponin in BALB/c mice
(Nishimura et al., 1999), while C57BL/6 developed a lupus-
like autoimmune disease (Nishimura et al., 2001). In humans,
polymorphisms in the PD-1 genewere also associatedwith suscep-
tibility to several autoimmune diseases including systemic lupus
erythematosus (Prokunina et al., 2002), type I diabetes (Nielsen
et al., 2003), and multiple sclerosis (Kroner et al., 2005). These
observations were supported by functional studies demonstrating
the contribution of the PD-L1/PD-L2/PD-1 pathway to central
tolerance. In the thymus, interactions between PD-1, expressed
by CD4−CD8− thymocytes, and PD-L1 broadly expressed in the
thymic cortex, were deemed crucial in regulating positive selec-
tion (Nishimura et al., 2000). PD-1 was also shown to participate
in thymic negative selection (Blank et al., 2003). Gene expres-
sion proﬁling studies of central tolerance in non-obese diabetic
(NOD) mice also implicated PD-1 and PD-L1 in central toler-
ance (Zucchelli et al., 2005). PD-L1/PD-L2/ PD-1 pathway also
contributes to peripheral tolerance through multiple mechanisms.
Self-reactive CD8+ T cells lacking PD-1 display increased respon-
siveness to self-antigens presented by resting DCs, suggesting that
DC-expressed PD-L1 and PD-L2 may control T cell activation
(Probst et al., 2005). PD-L1/PD-L2/PD-1 pathway can also regu-
late reactivation, expansion, and functions of effector T cells (Keir
et al., 2006). Additionally, PD-1 triggering of TCR-stimulated,
transforming growth factor-beta (TGF-β)-treated T cells pro-
foundly enhanced the de novo generation of Foxp3+ Tregs from
CD4+ naïve precursors. Further engagement of PD-L1 on the
iTregs sustained Foxp3 expression and enhanced the suppressive
capacity of these cells (Francisco et al., 2009). Consistently, PD-
L1 was shown to mediate the effects of the immune suppressant
vitamin D (VitD). DCs treated with VitD were shown to induce
IL-10 producing Tregs in a PD-L1-dependent mechanism (Unger
et al., 2009). Interactions between PD-1 and PD-L1 are also pro-
posed to maintain tolerance by modifying DC–T cell contact.
PD-1 ligation was shown to inhibit the TCR-induced stop sig-
nals, disrupting the stable DC–T cell contact and subsequently
allowing tolerized T cells to move freely and prohibiting clustering
around antigen-bearing DCs (Fife et al., 2009). Another plausible
mechanism for PD-L1/PD-L2/PD-1 pathway-induced tolerance is
that PD-L1 expressed by Tregs would engage PD-1 expressed by
DCs and modulate DC function and thereby impeding immune
responses (Francisco et al., 2010).
The inhibitory effects of PD-L1/PD-L2/PD-1 pathway can be
hijacked by tumors to evade anti-tumor immune responses. PD-
L1 expression has been conﬁrmed on many tumors including
glioblastoma and melanoma as well as cancers of the head and
neck, lung, ovary, colon, stomach, kidney, and breast. High
expression PD-L1 levels by tumor cells, tumor-inﬁltrating lym-
phocytes, or both associated with aggressive tumor behavior,
poor prognosis, and elevated risk of mortality (Zang and Alli-
son, 2007). Moreover, DCs generated from peripheral blood of
ovarian cancer patients displayed high levels of PD-L1, prompt-
ing impaired T cells responses, which were restored by blocking
PD-L1/PD-1 interactions (Curiel et al., 2003). In vivo, forced PD-
L1 expression by squamous cancer cells rendered them resistant
to T cell-mediated immunity. This resistance, however, was bro-
ken upon treatment with anti-PD-L1 blocking antibodies (Strome
et al., 2003). A recent study also revealed that platinum based
chemotherapeutics enhanced anti-tumor T cell responses by dis-
rupting PD-L2/PD-1 interactions through reducing PD-L2 levels
on both DCs and tumor cells (Lesterhuis et al., 2011). These
experimental observations prompted the development of human-
ized anti-PD-1 and anti-PD-L1 antibodies for clinical application.
Early stage clinical trials with these antibodies demonstrated clin-
ical activity, which was characterized by durability accompanied
with minimal side effects (Zitvogel and Kroemer, 2012).
There is also evidence that viral infections can make use of
PD-L1/PD-L2/PD-1 pathway. Animal models of chronic viral
infections had elevated PD-1 expression on exhausted viral
antigen-speciﬁc T cells. The activity of these T cells was restored
following PD-L1 blocking, suggesting a novel strategy for combat-
ing chronic viral infections (Barber et al., 2006).
In line with its inhibitory role, PD-L1/PD-L2/PD-1 pathway
can be harnessed for the induction of tolerance when needed.
Administration of recombinant PD-L1-Ig, with agonistic effect for
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PD-1, prolonged the survival of cardiac allografts in mice (Ozkay-
nak et al., 2002). Furthermore, PD-L1 expression on murine liver
allografts is central for spontaneous tolerance (Morita et al., 2010).
B7-H3 PATHWAY
B7-H3 belongs to the B7 family of co-stimulatory molecules. Sim-
ilar to other Ig superfamily members, B7-H3 is a transmembrane
molecule. It possesses a short cytoplasmic tail with no known
signaling domain. B7-H3 is expressed on a wide a variety of tis-
sues and tumor cell lines. However, its expression on leukocytes
is only detectable following stimulation. B7-H3 expression can
be induced on DCs and monocytes by inﬂammatory cytokines,
whereas a combination of phorbol myristate acetate and iono-
mycin can induce it on T cells. B7-H3 was shown to bind a
receptor expressed by activated T cells. This receptor is distinct
from CD28, CTLA-4, ICOS, and PD-1 and yet to be identiﬁed
(Chapoval et al., 2001). Triggering receptor expressed on myeloid
cells (TREM)-like transcript 2 (TLT-2), constitutively expressed
by CD8+ T cells and activation-induced on CD4+ T cells, was
proposed to be the binding partner of B7-H3 (Hashiguchi et al.,
2008). However, this was strongly refuted by another study pro-
viding evidence of non-existing interaction between B7-H3 and
TLT-2 (Leitner et al., 2009). Initially, B7-H3 was suggested to be
a positive co-stimulatory molecule that induces T cell prolifera-
tion, IFN-γ production and CTL generation in humans (Chapoval
et al., 2001). Nevertheless, this was contradicted by another study
demonstrating that B7-H3 is a potently inhibited T cell stimula-
tion under different conditions and regardless of the stimulation
status of the T cells in question (Leitner et al., 2009). This is
corroborated by data from murine studies where applying an
agonistic fusion protein, B7-H3-Ig, was shown to inhibit pro-
liferation, IL-2 and IFN-γ production of TCR-stimulated T cells.
This inhibitory effect was demonstrated by exacerbated airway
inﬂammation in B7-H3-deﬁcient mice compared to wild type
counterparts (Suh et al., 2003). Moreover, blocking B7-H3 caused
enhanced T cell proliferation in vitro and worsened EAE in vivo.
This effect may be explained by the inhibitory inﬂuence of B7-H3
signaling over NF-κB, NFAT, and AP-1 that are involved in regu-
lating T cell activation (Prasad et al., 2004). Notably, the effects
of B7-H3 were overridden by CD28 co-stimulation, implying
that B7-H3 functions optimally in the absence of co-stimulation
(Suh et al., 2003). Of interest, tumors are suggested to hijack the
B7-H3 to evade anti-tumor immune responses. This is demon-
strated by increased disease severity when cancer cells upregulated
B7-H3 expression (Hofmeyer et al., 2008). Collectively, further
characterization of the B7-H3 pathway is required to resolve func-
tional discrepancies, which may be explained by the existence
of two receptors for B7-H3 with opposite functions, yet to be
identiﬁed.
B7-H4 PATHWAY
B7-H4 is the last among the B7 family members that was identi-
ﬁed. Unlike other B7 family members, which are type I membrane
molecules, B7-H4 is characterized by a glycosylphosphatidylinos-
itol (GPI) domain that links to the cell membrane (Prasad et al.,
2003). In humans, B7-H4 mRNA was detected in a variety of tis-
sues. However, immunohistochemical analysis did not reveal any
B7-H4 protein expression by these tissues. Likewise, no B7-H4
expression could be detected on freshly isolated T cells, B cells,
monocytes, and DCs, but it was induced after activating these
cells in vitro. The ligand of B7-H4 has not been identiﬁed yet,
but it is suggested to be expressed by stimulated T cells and to
be distinct from other CD28 family members (Sica et al., 2003).
B7-H4 is widely regarded as a co-inhibitory molecule. Indeed,
treatment of TCR-stimulated T cells by a fusion B7-H4-Ig protein
resulted in inhibited T cell proliferation and cytokine production,
an effect that required B7-H4 cross-linking (Sica et al., 2003). The
inhibitory effects of B7-H4 are proposed to arise from arrested cell
cycle progression in T cells (Sica et al., 2003), and impaired induc-
tion of JunB, known for its role in inducing IL-2 production in
activated T cells (Prasad et al., 2003). A recent study also showed
that B7-H4 signaling inhibits phosphorylation of MAP kinases,
ERK, p38, Jun N-terminal kinase (JNK), and Akt, usually elicited
upon TCR triggering of T cells (Wang et al., 2012a).
In line with in vitro ﬁndings, mice suffering from graft
versus host disease demonstrated prolonged survival upon the
in vivo application of B7-H4-Ig (Sica et al., 2003). Expectedly,
in vivo administration of an antagonizing antibody against B7-H4
blocked the inhibitory effect of B7-H4 pathway and led to accel-
erated disease development in a mouse model of EAE (Prasad
et al., 2003). Furthermore, B7-H4-deﬁcient mice showed better
control of Leishmania major infection as Th1 responses were aug-
mented in these mice (Suh et al., 2006). B7-H4 deﬁciency also
enhanced neutrophils-mediated immunity, implying that B7-H4
may have a role in regulating innate immunity too (Zhu et al.,
2009). In addition to its role as a co-inhibitory molecule, B7-H4
seems to mediate the effect of Tregs. It was shown that Tregs, but
not conventional T cells, induce high levels of IL-10 production
by APCs and consequently trigger B7-H4 expression that ren-
ders these APCs immunosuppressive (Kryczek et al., 2006a). The
overall tolerogenic effect of B7-H4 can be exploited by tumors
to evade immune responses. B7-H4 expression was reported for
several tumors including lung cancer, ovarian cancer (Choi et al.,
2003), gastric cancer (Jiang et al., 2010), and tumor-associated
macrophages (Kryczek et al., 2006b). Blockade of B7-H4 on these
macrophages was actually effective in reversing their suppressive
effect and restored anti-tumor T cell immunity (Kryczek et al.,
2006b). Additionally, manipulating B7-H4 pathway has poten-
tial in the ﬁeld of transplantation. A recent study showed that
B7-H4 expression was shown to prolong islet allograft survival in
mice (Wang et al., 2012b). Thus, the B7-H4 pathway serves as an
interesting therapeutic target in different diseases, though several
aspects of this pathway remain elusive.
HVEM/BTLA/CD160 PATHWAY
As mentioned earlier, the molecules HVEM, BTLA, CD160, and
LIGHT interact directly with each other forming a complex path-
way network regulating adaptive immune responses. HVEM,
expressed by immature DCs, can provide negative co-stimulatory
signals through binding to its ligands BTLA and CD160 on T cells
(Ware and Sedy, 2011). BTLA belongs to the Ig superfamily and
is a structural homolog of CTLA-4 and PD-1. It is also a trans-
membrane glycoprotein that can be phosphorylated on tyrosines
located in conserved cytoplasmic ITIM motif (Watanabe et al.,
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2003). T cell expression of BTLAwas shown to be very lowonnaïve
cells. However, it is upregulated upon antigen-stimulation peaking
at day 2 and declining around day 7 post-stimulation. This expres-
sion can be retrieved upon secondary stimulation of activated T
cells. Interestingly, anergic T cells and Th1 cells demonstrated high
BTLA expression unlike Th2 cells and Tregs that have low BTLA
expression (Hurchla et al., 2005). The unique BTLA expression
pattern and expression kinetics indicate that BTLA may interfere
at certain stages of T cell activation with speciﬁcity to certain types
of effector T cells.
Herpes virus entry mediator delivers its inhibitory signal to T
cells by binding to BTLA,which induces the phosphorylation of its
ITIM domain and the recruitment of SHP-2, leading to attenuated
antigen-driven T cell activation (Sedy et al., 2005). In addition to
inhibiting T cell responses, there is evidence that HVEM/BTLA
pathway promotes T cell survival in a mechanism dependent on
NF-κB activation (Cheung et al., 2009). Interestingly, BTLA was
also shown tomediate Treg suppression by interactingwithHVEM
expressed byTregs. This was supported by showing that Tregs from
HVEM-deﬁcient mice had lower suppressor activity and that wild
type Tregs failed to suppress effector T cells from BTLA-deﬁcient
mice (Tao et al., 2008). The inhibitory effects of BTLA are also
observed in vivo. In an EAE model, BTLA-deﬁcient mice displayed
increased severity and persistence of disease when compared with
wild type controls (Watanabe et al., 2003). BTLA deﬁciency was
also reported to exacerbate allergic airway inﬂammation (Dep-
pong et al., 2006) and to cause the development of auto-antibodies
leading to a hepatitis-like syndromewith advancing age (Oya et al.,
2008). Moreover, a single-nucleotide polymorphism (SNP) in the
ITIM region of BTLA was reported to associate with increased
susceptibility to rheumatoid arthritis (Lin et al., 2006). Another
study also revealed an association between another BTLA SNP and
rheumatoid arthritis, but not with systemic lupus erythemato-
sus or Sjogren’s syndrome (Oki et al., 2011). Similar to B7-H3
and B7-H4, the inhibitory effects of BTLA can be exploited by
tumors to evade immunity. Melanoma-speciﬁc CD8+ T cells were
shown to persistently express BTLA. Interrupted BTLA signaling,
achieved by applying CpG oligonucleotide vaccine formulations,
lead to functional recovery of melanoma-speciﬁc CD8+ T cells
(Derre et al., 2010).
Herpes virus entry mediator can also interact with CD160, a
GPI anchored membrane molecule that is mainly expressed by
CD8+ T cells and activated CD4+ T cells. Cross-linking CD160
with a speciﬁc antibodyon stimulatedTcellswas shown to strongly
inhibit T cell proliferation and cytokine production. Similarly,
the inhibitory effect of CD160 was also elicited by binding to
its ligand HVEM (Cai et al., 2008). Although both BTLA and
CD160 bind to the cysteine-rich domain-1 (CRD-1) of HVEM
with comparable afﬁnity, CD160 dissociates from HVEM at a
slower rate compared to BTLA. Moreover, mutagenesis study of
HVEM revealed that CD160 has a distinct binding site on HVEM,
albeit overlapping with BTLA (Kojima et al., 2011). Those differ-
ences between CD160 and BTLA, though subtle, suggest that these
molecules do not have redundant functions. Further delineation
of the elusive HVEM/CD160 pathway and its functional implica-
tions are required to unravel its speciﬁc role in regulating immune
responses.
ILT3 AND ILT4/HLA-G PATHWAYS
The inhibitory receptor Ig-like transcript-3 (ILT3; Cella et al.,
1997) and ILT4 (Colonna et al., 1998), both expressed by mono-
cytes, macrophages, and DCs, belong to a family of Ig-like
inhibitory receptors that are closely related to the killer cell
inhibitory receptors. Both ILT3 and ILT4 were shown to transmit
signal through a long cytoplasmic tail containing ITIM motifs,
which inhibit cell activation by recruiting the protein phosphatase
SHP-1 (Cella et al., 1997; Colonna et al., 1998). In the case of ILT3,
the extracellular region consists of two Ig-like domains, which are
speculated to contain the putative binding site of the yet to be
identiﬁed ILT3 ligand (Cella et al., 1997). On the other hand, the
binding partner of ILT4 was shown to be the MHC class I molecule
human leukocyte antigen G (HLA-G; Colonna et al., 1998). In
addition to triggering an inhibitory signal, ILT3 cross-linking was
shown to lead to its internalization and delivery into an antigen
presenting compartment, suggesting a role in antigen processing
(Cella et al., 1997). DC expression of ILT3 and ILT4 was shown to
be induced under the effect of CD8+CD28− alloantigen-speciﬁc
T suppressor cells (Chang et al., 2002). Immature monocyte-
derived DCs (MoDCs) also upregulated ILT3 and ILT4 expression
upon treatment with either IL-10 or/and IFN-α (Manavalan
et al., 2003). VitD treatment only induced ILT3 expression in
MoDCs (Manavalan et al., 2003) and primary human blood
BDCA1+ DCs (Chu et al., 2012). Expectedly, ILT3 expression, by
both MoDCs and pDCs, was downregulated following activation
(Ju et al., 2004).
Tolerogenic DCs over-expressing ILT3 or ILT4 demonstrated
impaired NF-κB activation and consequently reduced transcrip-
tion capacity of NF-κB-dependent co-stimulatory molecules
(Chang et al., 2002). ThoseDCswere shown to be capable of trans-
forming alloreactive effector T cells into antigen-speciﬁc Tregs
(Manavalan et al., 2003). Similarly, triggering ILT4 by HLA-G
tetramers was shown to impair maturation and T cell stimulatory
capacity of human DCs (Liang and Horuzsko, 2003). Interest-
ingly, ILT3 was shown to maintain its T cell inhibitory effect when
it was expressed as soluble ILT3-Fc that lacks ILT3’s cytoplasmic
tail, indicating that ILT3 delivers its inhibitory signal by bind-
ing to its partner on activated T cells (Kim-Schulze et al., 2006).
Recently it was shown that ILT3 capacity to convert T cells into
suppressive cells is dependent on BCL6 signaling in these T cells
(Chang et al., 2010). ILT3 is also proposed to be important for
controlling inﬂammation, as silencing ILT3 expression in DCs
enhances TLR responsiveness, which is reﬂected by enhanced
secretion of inﬂammatory cytokines such as IL-1α, IL-1β, IL-6,
and IFN-α. ILT3-silenced DCs could also attract more lympho-
cytes by secreting high levels of the chemokines CXCL10 and
CXCL11 in response to TLR ligation. Eventually, impaired ILT3
expression in DCs rendered them more stimulatory for T cells,
which also secreted higher levels of cytokines like IFN-γ and IL-
17 (Chang et al., 2009). Another suggested mechanism by which
both ILT3 and ILT4 contribute to tolerance is by possibly mediat-
ing the effects of IDO. DCs cultured in tryptophan-deprived local
environment upregulated the expression of ILT3 and ILT4, favor-
ing the development of Foxp3+ Tregs (Brenk et al., 2009). Finally,
ILT4 was shown to be central for the development of type I Tregs,
induced by IL-10-treated DCs (Gregori et al., 2010).
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The effects of ILT3 and ILT4/HLA-G pathways are also evi-
denced in vivo. Immune modulation exerted by ILT4/HLA-G
interactions is believed to mediate maternal tolerance toward
the semi allogenic fetus (Hunt et al., 2005). Moreover, in vivo
treatment with VitD was shown to upregulate the expression of
ILT3 on DCs in healing psoriatic lesions. Nevertheless, ILT3 was
revealed to be dispensable for the induction of Tregs and com-
pletely overridden by the inhibitory effects of VitD (Penna et al.,
2005). Consistently, maternal VitD intake during pregnancy was
found to enhance ILT3 and ILT4 gene expression levels in cord
blood, pointing out a plausible mechanism for early induction
of immune tolerance (Rochat et al., 2010). Enhanced ILT3 and
ILT4 levels were also observed at an early stage of venom-speciﬁc
immunotherapy, implying a possible role in inducing tolerance
toward allergic reactions (Bussmann et al., 2010). Owed to its
inhibitory effects, ILT3 is suggested to be employed by tumors
as a mean of evading anti-tumor immunity. Indeed, soluble ILT3
protein was found at high levels in the serum of patients with
melanoma, and carcinomas of the colon, rectum, and pancreas
produce. This soluble ILT3 was active in inducing suppressor
CD8+ T cells that block anti-tumor immunity, which was restored
upon blocking or depleting ILT3 (Suciu-Foca et al., 2007). A sim-
ilar mechanism is also utilized by viruses, as demonstrated by a
point mutation in one of HIV Gag epitopes that increased bind-
ing to ILT4 and consequently programed myelomonocytic cells to
become tolerogenic (Lichterfeld et al., 2007). The inhibitory effects
of ILT3 can also be harnessed for allograft acceptance. Indeed, sol-
uble recombinant ILT3-Fc was shown to suppress T cell-mediated
rejection of allogenic islet transplants inmice (Vlad et al., 2008). In
correlation to its inhibitory effect, blood monocytes during mul-
tiple sclerosis relapses demonstrated lower ILT3 expression, which
was restored upon treatment with IFN-β, unraveling a plausible
therapeutic target in the treatment of multiple sclerosis (Jensen
et al., 2010). Similarly, a SNP in the ILT3 extracellular region
was correlated with low surface expression and increased serum
cytokine levels in lupus patients (Jensen et al., 2012).
CONCLUDING REMARKS AND FUTURE PROSPECTS
Since the identiﬁcation of the CD80/CD86/CD28 classical co-
stimulatory pathway, the concept of DC-derived signal II was dra-
matically expanded to accommodate the ever increasing number
of newly discovered co-stimulatory and co-inhibitory pathways.
An increasing body of reports reﬂects the complexity of these
pathways and implies possible interactions to form a sophisticated
network controlling adaptive immune responses. The existence of
multiple co-stimulatory and co-inhibitory pathways postulates for
overlapping functions. Nevertheless, this notion of redundancy
should be considered carefully. The components of these path-
ways have distinct expression patterns and kinetics, which means
that these pathways are not simultaneously operative. In addition,
mobilizing these pathways can trigger distinct signaling cascades
and thereby leading to variable outcomes.
Dendritic cell expression of co-stimulatory and co-inhibitory
molecules is dictated by several factors. The speciﬁc type of DC
is a major determinant of this expression. In humans, DCs are
classiﬁed into groups basedonorigin, speciﬁc expressionof certain
surface markers, and functional properties. For example, human
blood DCs are divided into two major subsets: pDCs and myeloid
DCs (myDCs). The latter can be further divided into three subsets:
BDCA1+ DCs, BDCA3+ DCs, and CD16+ DCs. In parallel, skin
DCs are also classiﬁed into epidermal LCs, dermal CD1a+ DCs,
and dermal CD14+ DCs. Similar classiﬁcation can be expected
in other tissue-resident DCs. Most of the ﬁndings concerning co-
stimulatory and co-inhibitory molecules in humans were based on
experiments performed on the in vitro generated MoDCs, which
serve as a great tool for delineating immunological functions and
mechanisms. However, there are strong indications of differential
expression of co-stimulatory and co-inhibitory molecules among
different DC subsets. These variations can be partially related to
the intrinsic qualities of every DC subset. For instance, pDCs and
LCs lack the expression of TLR4, and consequently they are not
able to upregulate CD80 and CD86, observed in other subsets in
response to lipopolysaccharide (LPS).
Another central determinant of co-stimulatory and co-
inhibitory molecules expression by DCs is the type of stimulus,
to which DCs are exposed. As mentioned earlier, DCs respond
to pathogen stimulation by upregulating CD80 and CD86. How-
ever, there are indications that certain co-stimulatory molecules
are strictly expressed upon activation with a speciﬁc class of
pathogens. A clear example is CD70 expression by LCs upon
TLR3 triggering by double-stranded RNA derived from viruses,
granting LCs advantage in eliciting strong anti-viral CD8+ T cell
responses. Although dermal DCs and MoDCs express TLR3, they
do not upregulate CD70 in response to double-stranded RNA,
implying a combined effect of the type of stimulus and the type
of DC in inducing CD70 expression. Similarly, pDC stimulation
with CpG B, a TLR9 ligand, induced the expression of CD70,
which was not observed using another type of stimulation or in
other DC subsets (Shaw et al., 2010). Another example demon-
strating the effect of pathogenic stimulation is the upregulation
of OX40L only upon exposure to the soluble egg antigen from
the parasite Schistosoma mansoni. Furthermore, DC treatment
with certain immune modulating agents can inﬂuence the expres-
sion of co-stimulatory and co-inhibitory molecules. VitD-treated
DCs displayed induced expression of PD-L1 and ILT3, concur-
rent with inhibited expression of CD80 and CD86. On the other
hand, DCs under the inﬂuence of IL-10 had normal expression
levels of CD80 and CD86 but over-expressed ILT3 and ILT4. It
is also evident that DCs are strongly inﬂuenced by cues derived
from the local environment. The well-documented effect of VitD,
the major component of local skin milieu, is a clear example.
The inﬂuence of other known tissue-related environmental fac-
tors on co-stimulation requires further elucidation. Thus, optimal
understanding of the role of DC-derived signal II requires deter-
mining the total repertoire of co-stimulatory and co-inhibitory
molecules expressed by different DC subsets and under different
conditions.
In addition to the differential DC expression of co-stimulatory
and co-inhibitory molecules, the respective ligands of these
molecules are also described to be expressed by T cells follow-
ing different kinetics. Some of these ligands are constitutively
expressed, like CD28, whereas others are restricted to recently
TCR-activated T cells such as 4-1BB and GITR. Furthermore,
some of these ligands were shown to be exclusively expressed by
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certain types of effector T cells, like the Th1-speciﬁc expression of
TIM3. Taken together, the different expression modalities of the
co-stimulatory and co-inhibitory pathway constituents imply that
these pathways are mobilized at certain stages of T cell priming
and under speciﬁc conditions.
Despite the stimulatory or inhibitory nature of signal II, there
are some indications pointing out a role in T cell polarization,
typically undertaken by cytokine-based signal III. For instance,
OX-40L/OX-40 and 4-1BBL/4-1BB pathways are proposed to
promote the differentiation of Th2 and Th1 effector cells, respec-
tively. Nevertheless, the observed polarizing effect was in many
occasions revealed to be the mere outcome of promoted T cell sur-
vival rather than active polarization signaling mediated by these
co-stimulatory or co-inhibitory molecules. Therefore, reported
contributions of signal II to T cell differentiation should be
interpreted carefully and further investigated.
The vast immunological consequences of signal II have trans-
formed its pathways, both stimulatory and inhibitory, into
therapeutic targets for the treatment of a wide variety of diseases.
Mobilizing co-stimulatory pathways and blocking co-inhibitory
interactions showed promising results in promoting anti-tumor
immunity and it is proposed to be beneﬁcial for the treatment of
chronic viral responses. Assuming that mature DCs provide opti-
mal positive co-stimulatory signals while priming anti-tumor T
cells, blocking co-inhibitory pathways may augment the efﬁcacy
of these T cells. In that respect, concurrent targeting of multi-
ple co-inhibitory pathways might be necessary. Neutralizing the
key inhibitory check point CTLA-4 permits extensive primary
T cell activation, but by itself is not sufﬁcient for driving an
anti-tumor immune response, especially in the case of advanced
tumors. However, the additional circumvention of yet another
co-inhibitory check point, which is dictated by the tumor itself,
may solve this problem. Selecting the second inhibitory target
would highly depend on the type of the treated tumor, as differ-
ent types of tumors were revealed to preferentially express certain
co-inhibitory receptors (PD-L1, PD-L2, B7-H3, etc.). The syn-
ergistic effects of such a combinatorial blocking strategy may not
onlymount efﬁcient anti-tumorT cell responses, but also allow the
persistence of such responses within the local tumor environment.
On the other hand, promoting tolerance by blocking activation
and mobilizing co-inhibitory pathways is a promising strategy for
raising allograft tolerance. Similarly, immune suppressant agents
were also revealed to manipulate these pathways in a compara-
ble manner to induce tolerance. Nevertheless, these therapeutic
modalities should be applied with great care to avoid any possible
adverse effects like inducing susceptibility to infection or autoim-
mune reactions. Targeting these therapies to a speciﬁc pathway or
a speciﬁc cellular compartment, like a certain DC subset, may be
an option to bypass any possible complications.
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